These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21994347)

  • 21. Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease.
    Zapolski T; Waciński P; Kondracki B; Rychta E; Buraczyńska MJ; Wysokiński A
    Kardiol Pol; 2011; 69(4):319-26. PubMed ID: 21523662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
    Zarich SW
    Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reducing the "domino effect" of the metabolic syndrome.
    Freeman JS
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):inside front cover, S1-3. PubMed ID: 17784528
    [No Abstract]   [Full Text] [Related]  

  • 24. Soluble CD36- a marker of the (pathophysiological) role of CD36 in the metabolic syndrome?
    Koonen DP; Jensen MK; Handberg A
    Arch Physiol Biochem; 2011 May; 117(2):57-63. PubMed ID: 21250778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body composition, metabolic syndrome and testosterone in ageing men.
    Allan CA; Strauss BJ; McLachlan RI
    Int J Impot Res; 2007; 19(5):448-57. PubMed ID: 17554396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease.
    Roos CJ; Quax PH; Jukema JW
    Biomark Med; 2012 Feb; 6(1):35-52. PubMed ID: 22296195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
    Chan JC; Tong PC; Critchley JA
    Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications.
    Savoia C; Volpe M; Alonzo A; Rossi C; Rubattu S
    Clin Sci (Lond); 2009 Nov; 118(4):231-40. PubMed ID: 19886866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammatory mediators involved in the progression of the metabolic syndrome.
    Ma K; Jin X; Liang X; Zhao Q; Zhang X
    Diabetes Metab Res Rev; 2012 Jul; 28(5):388-94. PubMed ID: 22389088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states.
    Alam I; Lewis K; Stephens JW; Baxter JN
    Obes Rev; 2007 Mar; 8(2):119-27. PubMed ID: 17300278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.
    Koh KK; Han SH; Quon MJ
    J Am Coll Cardiol; 2005 Dec; 46(11):1978-85. PubMed ID: 16325028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanisms for vascular injury in the metabolic syndrome.
    Yamagishi S; Nakamura K; Jinnouchi Y; Takenaka K; Imaizumi T
    Drugs Exp Clin Res; 2005; 31(3):123-9. PubMed ID: 16033251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinal vascular manifestations of metabolic disorders.
    Nguyen TT; Wong TY
    Trends Endocrinol Metab; 2006 Sep; 17(7):262-8. PubMed ID: 16890449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes.
    Deedwania PC
    Cardiol Clin; 2004 Nov; 22(4):505-9, v. PubMed ID: 15501619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance, metabolic syndrome and endothelial dysfunction.
    Bigazzi R; Bianchi S
    J Nephrol; 2007; 20(1):10-4. PubMed ID: 17347967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes mellitus, hypertension and ageing: the ionic hypothesis of ageing and cardiovascular-metabolic diseases.
    Barbagallo M; Resnick LM; Dominguez LJ; Licata G
    Diabetes Metab; 1997 Sep; 23(4):281-94. PubMed ID: 9342541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome.
    Otani H
    Antioxid Redox Signal; 2011 Oct; 15(7):1911-26. PubMed ID: 21126197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome.
    Correia ML; Rahmouni K
    Diabetes Obes Metab; 2006 Nov; 8(6):603-10. PubMed ID: 17026484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging role of microRNAs in cardiovascular disease.
    Maegdefessel L
    J Intern Med; 2014 Dec; 276(6):633-44. PubMed ID: 25160930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional foods and nutraceuticals as therapeutic tools for the treatment of diet-related diseases.
    Magrone T; Perez de Heredia F; Jirillo E; Morabito G; Marcos A; Serafini M
    Can J Physiol Pharmacol; 2013 Jun; 91(6):387-96. PubMed ID: 23745830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.